Cyprium Therapeutics
New York, US · Delaware corporation
Cyprium Therapeutics is a biopharmaceutical company developing treatments for rare pediatric diseases, including CUTX-101 (copper histidinate) for Menkes disease. It is a subsidiary of Fortress Biotech.
Founders & leadership
LY
Lung YamExecutive
Board
LA
Lindsay A. RosenwaldBoard director
Reported raises · per SEC filings
Form D private placements$7M disclosed across 1 round · 2020
▶$7MraisedOct 2021 · 75 investors · Other Health CareRule 506(b)
▶$7MraisedOct 2021 · 75 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lung YamExecutive Officer
- Lindsay A. RosenwaldDirector
- Offering amount
- $7M
- Amount sold
- $7M
- Minimum investment
- $25K
- Sales commissions
- $870K
- Placement agents
- National Securities Corporation
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapFortress Biotech12 shared keywordsFortress Biotech is a biopharmaceutical company that develops and commercializes pharmaceutical products, maintaining a pipeline of both revenue-generating commercial-stage products and development-stage drug candidates. It advances its products through partnerships within the pharmaceutical industry.
Medscape12 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Companies competing with Cyprium Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cyprium Therapeutics do?
- Cyprium Therapeutics is a biopharmaceutical company developing treatments for rare pediatric diseases, including CUTX-101 (copper histidinate) for Menkes disease. It is a subsidiary of Fortress Biotech.
- How much funding has Cyprium Therapeutics raised?
- Cyprium Therapeutics has disclosed $7M raised across 1 round.
- Where is Cyprium Therapeutics headquartered?
- Cyprium Therapeutics is headquartered in New York, US.